# Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06194656/  
OnCo record `nct06194656` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cetuximab in head and neck squamous cell carcinoma, run by Shanghai Institute Of Biological Products, now recruiting.

## Summary

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06194656 by Shanghai Institute Of Biological Products, with 81 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-07-30. Interventions recorded: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06194656
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SIBP-03 Injection Combined With Cetuximab in Patients With Recurrent/Metastatic Advanced Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)
- Sponsor: Shanghai Institute Of Biological Products
- Enrolled: 81

## Sources

- ClinicalTrials.gov NCT06194656: https://clinicaltrials.gov/study/NCT06194656

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/)

---
JSON: https://onco.cc/api/v1/entities/nct06194656.json